Recent years have seen a surge in innovation in drug delivery, particularly for chronic conditions, where rising healthcare costs exacerbate the challenge of managing already expensive-to-treat conditions.
U.S. Rep. David Schweikert called for making GLP-1s more widely accessible, claiming this will help more people lose weight and, in turn, take pressure off healthcare costs in the U.S.